Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ArthroDUR

Financiado

Cerrado

Bifunctional and regeneratively active biomaterial Towards an ultimate solution...

Bifunctional and regeneratively active biomaterial Towards an ultimate solution for osteoarthritis treatment Osteoarthritis (OA) is the most common form of arthritis of the joints, affecting over 70 million EU citizens. At present, no cure for OA is available; only symptomatic therapies may help to ameliorate this painful disorder. OA af... ver más

28/02/2019

UMC-Mainz

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERGUN... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2019-02-28

ERC-2017-PoC: ERC-Proof of Concept

I+D

Cerrada hace 8 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

UMC-Mainz

150.00K€ | Lider

NEW SOFT NETWORKS

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

REBOOT First in class implants for bone regeneration surgery after... 4M€ Cerrado

MICARTREGEN Multi biofunctional implants for in situ cartilage regenerat... 231K€ Cerrado

GAMBA Gene Activated Matrices for Bone and Cartilage Regeneration... 4M€ Cerrado

EOBOTE Study of Endothelial and Osteoclastic cells cooperation for... 75K€ Cerrado

PTQ-09-01-00016 Cementos Biocompatibles para Regeneracion Osea 71K€ Cerrado

ANCHOR Articular cartilage regeneration through the recruitment of... 150K€ Cerrado

Duración del proyecto: 18 meses Fecha Inicio: 2017-08-25
Fecha Fin: 2019-02-28

Líder del proyecto

UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERGUN... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 150K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Osteoarthritis (OA) is the most common form of arthritis of the joints, affecting over 70 million EU citizens. At present, no cure for OA is available; only symptomatic therapies may help to ameliorate this painful disorder. OA affects the integrity of the cartilage and progresses to an increased damage in its surrounding tissues, inclusive bone, and to inflammation of the synovial tissue. The latter reaction is caused by an accumulation of bone splinters. The therapy of choice would be – if available – bidirectional: first, regeneration of the damaged cartilage (by implants) and second, dissolution of the bone fragments (by injections). This proposal presents for the first time this two-fold solution. Within my ERC Advanced Grant BIOSILICA (No. 268476) we disclosed that biosilica elicits morphogenetic activity in cells involved in connective tissue formation. The effect of silica is augmented by another natural inorganic polymer, by polyphosphate (polyP), which is synthesized in most animal cells, especially blood platelets that accumulate in damaged bone and cartilage. polyP acts as metabolic fuel for the synthesis of the extracellular inorganic and organic skeletal and cartilage tissues. Our strategy is to combine and to amplify the beneficial properties of these two polymers, biosilica and polyP, their morphogenetic activity with their structure-forming/guiding activity, by applying hybrid microparticles, consisting of silica and polyP. The proposed project will provide the proof-of-concept of this dual strategy, using silica and the amorphous Mg2+/Ca2+ salt of polyP together with hyaluronic acid, to dissolve firstly existing bone splinters in the synovial fluid (by injection), reducing the painful joint burden in osteoarthritis, and secondly to repair damaged cartilage with polyP/silica implants. This innovative material, injectable and implantable, will be developed to commercializable products for the benefit of the aging society.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores